For much of the past decade, the modern psychedelic renaissance has been accompanied by an unusually powerful media narrative.
Drugs once associated with counterculture and prohibition were being reconsidered by serious scientists, major universities and pharmaceutical companies. Early clinical studies suggested that compounds such as psilocybin and MDMA could open up new approaches to some of the most difficult conditions in mental health.
That coverage helped move psychedelics from the fringes of medicine into the mainstream. It attracted researchers, clinicians and entrepreneurs, drew significant investment into the sector and created a new vocabulary around psychedelic medicine, increasingly centred on clinical trials, regulatory pathways and commercial drug development rather than recreational use.
Now, a large-scale analysis of 25 years of media coverage suggests that the story is entering a different phase.
Researchers publishing in BJPsych Open analysed more than 3,300 news articles published between 2000 and 2025, using artificial intelligence to examine both the subject matter and sentiment of reporting about psychedelic drugs.
The results show just how dramatically interest in therapeutic psychedelics has grown, while also revealing a measurable decline in the overwhelmingly positive tone that characterised the height of the psychedelic renaissance.
The change does not necessarily mean the media has turned against psychedelic medicine. Instead, it reflects a sector that is attracting more scrutiny as promising research moves closer to the realities of clinical development, regulation and commercialisation.
From Counterculture to Clinical Medicine
The scale of the transformation is striking.
Between 2000 and 2009, just 13.3 per cent of the articles analysed by the researchers focused primarily on the therapeutic potential of psychedelics. Between 2020 and 2025, that figure had risen to 85.3 per cent.
In little more than a decade, the dominant media story had shifted from the cultural history of psychedelics towards their potential role in medicine.
The volume of coverage increased at the same time.
The researchers identified only four relevant URLs through Google News in 2000. By 2024, that figure had reached more than 3,100.
The acceleration coincided with the period in which psychedelic research began attracting mainstream attention, as clinical studies, major research institutions and emerging biotechnology companies helped push psychedelics into the centre of discussions about the future of mental healthcare.
Media coverage followed the research.
Stories increasingly focused on depression, PTSD, addiction and other psychiatric conditions, while terms including psychedelic-assisted therapy, clinical trials, psilocybin and MDMA became increasingly common.
For the industry, the attention was valuable. Public awareness grew, researchers gained a much larger audience for their work and companies were able to connect decades of neglected research with the enormous unmet need in mental healthcare.
But media attention has its own lifecycle.
The data suggests the most enthusiastic phase may have already passed.
The 2020 Peak
The researchers found that sentiment towards the therapeutic potential of psychedelics reached its highest level in 2020, when the average sentiment score across relevant articles was 80.8 out of 100.
Since then, the tone has become less positive.
By 2024, the average score had fallen to 74.3. The proportion of articles classified as negative or neutral also increased, from 3.6 per cent in 2020 to 20.9 per cent in 2024.
Those figures should not be interpreted as evidence that mainstream media coverage has turned against psychedelic medicine. The overwhelming majority of therapeutic coverage remained positive or neutral, while only a small proportion of the articles analysed were classified as negative.
What appears to have changed is the level of scrutiny.
Early coverage often centred on whether psychedelics could represent a fundamentally new approach to treating mental illness. As the sector has matured, the questions have become harder.
How robust are the clinical results? Can they be reproduced? How should trials be designed? What role does expectancy play? What happens when treatment moves outside specialised research environments? And how could psychedelic-assisted interventions actually fit into ordinary healthcare?
These questions require more than promising early-stage results or compelling patient stories.
They require evidence, regulatory approval, clinical infrastructure and ultimately the ability to demonstrate that a treatment can work reliably in the real world.
The Regulatory Reality Arrives
The change in media tone has coincided with a more complicated period for the psychedelic industry itself.
The early 2020s brought considerable expectations around the possibility of regulatory approval for new psychedelic treatments. By 2024, however, the sector had encountered a significantly more demanding regulatory environment.
One of the most consequential moments came when the US Food and Drug Administration declined to approve Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in the form submitted.
The decision highlighted the distance between promising clinical research and an approved medical product.
It also brought greater attention to trial methodology, safety, durability of benefit and the practical requirements involved in delivering psychedelic-assisted treatment.
The implications extend beyond MDMA.
Companies developing psilocybin, LSD, DMT and other psychedelic-based therapies face the same fundamental challenge: commercial opportunity ultimately depends on clinical and regulatory evidence.
A compelling biological mechanism, encouraging early-stage data or strong public interest can create momentum, but none is a substitute for the evidence required by regulators or the infrastructure required by healthcare systems.
That is increasingly becoming part of the media story as well.
AI Is Becoming a Tool for Tracking the Psychedelic Narrative
The study is notable not only for its findings, but also for the way the researchers analysed the coverage.
The team initially identified 3,747 URLs through Google News searches for the term “psychedelics”. After screening, 3,308 articles from more than 1,000 websites were included in the analysis.
Artificial intelligence was then used to classify the articles according to their focus and assess the sentiment of coverage relating to therapeutic psychedelics.
The researchers compared the AI-generated assessments with human ratings and found a high level of agreement, suggesting that AI can provide a practical way to analyse media narratives at a scale that would be difficult to achieve through conventional manual coding.
For a rapidly developing industry, that has potential applications beyond academic research.
Companies and investors have traditionally tracked media attention by counting stories, monitoring headlines and following mentions of particular companies or therapies.
A more sophisticated approach could examine how the narrative itself is changing: whether coverage is being driven by clinical evidence, regulatory decisions, investment activity, commercial developments or controversy, and whether the tone of that coverage is changing over time.
Media analysis could therefore become another source of industry intelligence.
Sentiment Is Not the Same as Scientific Evidence
There is an important limitation to what the study can tell us.
Positive media coverage does not necessarily mean the underlying science is strong. Negative coverage does not necessarily mean a therapy lacks merit.
A journalist can describe an excellent clinical trial in highly positive language, while a sceptical article might identify a genuine weakness in an otherwise promising research programme.
Sentiment measures the character of media coverage. It does not measure the validity of the science itself.
The researchers also acknowledge limitations associated with using Google News to identify articles. Google does not index every piece of journalism, while its ranking systems influence which material is surfaced to users.
The dataset therefore cannot be treated as a complete record of everything published about psychedelics around the world.
Even so, the scale and duration of the analysis make the broader trend difficult to dismiss.
Over 25 years, psychedelics have moved from being predominantly a cultural and recreational subject into an overwhelmingly medical and scientific one. At the same time, the exceptionally positive narrative surrounding their therapeutic potential has begun to moderate as the sector encounters the practical difficulties involved in turning experimental science into medicine.
The Next Phase Will Be About Proof
For the psychedelic industry, the most revealing part of the research may not be that media sentiment has declined, but what that change says about the industry’s position today.
The first phase of the renaissance was largely about rediscovery.
Researchers demonstrated that compounds dismissed or prohibited for decades could once again be studied, while early trials produced results that generated genuine excitement across psychiatry and neuroscience.
The next phase is more demanding.
Companies will need to demonstrate that their compounds can produce clinically meaningful outcomes in appropriately designed trials, that safety can be adequately characterised, that treatments can be manufactured consistently and that regulators can be satisfied.
Clinicians and healthcare systems will also need workable models for delivering these treatments.
Investors, meanwhile, will increasingly need to distinguish between companies with credible development programmes and businesses whose value is largely tied to exposure to the broader psychedelic narrative.
The media is likely to follow that transition.
Psychedelics are no longer being covered simply because they are unusual, controversial or culturally fascinating. They have become the subject of major clinical programmes, substantial investment and broader questions about the future of mental healthcare.
That creates a higher standard for the stories that come next.
The psychedelic renaissance is not necessarily losing momentum. It is moving into a stage where enthusiasm has to coexist with evidence, and scientific promise has to survive regulatory and commercial scrutiny.
For an industry that spent years trying to convince the world that psychedelics belonged in mainstream medicine, that is a significant change.
The question is no longer simply whether psychedelics can change mental healthcare.
It is whether the evidence, companies and healthcare systems developing around them can deliver on that promise.
